Doxorubicin Hydrochloride
Doxorubicin Hydrochloride is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Doxorubicin Hydrochloride; Generic name: DOXORUBICIN HYDROCHLORIDE; Manufacturer: Pfizer Laboratories Div Pfizer Inc.
| Brand name | Doxorubicin Hydrochloride |
|---|---|
| Generic name | DOXORUBICIN HYDROCHLORIDE |
| Manufacturer | Pfizer Laboratories Div Pfizer Inc |
| Used for | 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogeni |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Single agent : 60 to 75 mg/m 2 given intravenously every 21 days ( 2.2 ) • In combination : 40 to 75 mg/m 2 given intravenously every 21 to 28 days ( 2.2 ) • Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy ( 2.3 ) • Reduce dose in patients with hepatic impairment ( 2.4 ) 2.1 Recommended Dosage for Adjuvant Breast Cancer The recommended dosage of Doxorubicin Hydrochloride Injection is 60 mg/m 2 administered |
| Warnings | WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1%–20% for cumulative doses ranging from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further incre |
| Active ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00634b2b-4e48-4178-8877-28582af894ad |